Clinical Trial: CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects
Brief Summary: This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma
Detailed Summary: This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .
Sponsor: Sun Yat-sen University
Current Primary Outcome: Event Free Survival Rate [ Time Frame: 18 months ]
Original Primary Outcome: Event Free Survival Rate [ Time Frame: 18 months ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Sun Yat-sen University
Dates:
Date Received: December 15, 2014
Date Started: January 2009
Date Completion:
Last Updated: March 11, 2015
Last Verified: March 2015